Revitalizing psychiatric therapeutics

Neuropsychopharmacology

Volumn 39, Issue 1, 2014, Pages 220-229

  Hyman, Steven E ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

animal models; psychiatric genetics; stem cells

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); CHLORDIAZEPOXIDE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; IMIPRAMINE; INOSITOL 1 PHOSPHATASE; IPRONIAZID; LITHIUM; SEROTONIN TRANSPORTER; BIOLOGICAL MARKER;

AUTISM; BIPOLAR DISORDER; DNA SEQUENCE; DRUG DEVELOPMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; HUMAN; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; MENTAL DISORDERS; METABOLISM; PROCEDURES;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84890454893     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.181     Document Type: Review

References (66)

1. Genomes Project Consortium (2012). An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56-651000
2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. (1998). Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 155: 761-767
3. Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald A III, Noll DC et al. (2001). Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 58: 280-288
4. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K et al. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med 4: 127-152
5. Blackwood DH, Fordyce A, Walker MT St, Clair DM, Porteous DJ, Muir WJ (2001). Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: Clinical and P300 findings in a family. Am J Hum Genet 69: 428-433
6. Cade JFJ (1949). Lithium salts in the treatment of psychotic excitement. Med Aust 2: 349-352
7. Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70
8. Carter CS, Barch DM. CNTRICS Executive Committee (2012). Imaging biomarkers for treatment development for impaired cognition: Report of the sixth CNTRICS meeting: Biomarkers recommended for further development. Schizophr Bull 38: 26-33
9. Chung K, Wallace J, Kim SY, Kalyanasundaram S, Andalman AS, Davidson TJ et al. (2013). Structural and molecular interrogation of intact biological systems. Nature 497: 332-337
10. Church DM, Goodstadt L, Hillier LW, Zody MC, Goldstein S, She X et al. (2009). Lineage-specific biology revealed by a finished genome assembly of the mouse. PLoS Biol 7: E1000112
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264-1272
12. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823
13. Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C et al. (2011). Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet 7: E1002254
14. Cross-Disorder Group of the Psychiatric Genomics Consortium (2013). Identification of risk loci with shared effects on five major psychiatric disorders: A genomewide analysis. Lancet 381: 1371-1379
15. Deverteuil R, Lehmann HE (1958). Therapeutic trial of iproniazid (marsilid) in depressed and apathetic patients. Can Med Assoc J 78: 131-133
16. Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K et al. (2013). A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12: 238-251
17. Földy C, Malenka RC, Südhof TC (2013). Autism-Associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron 78: 498-509
18. Fox MD, Synder AZ, Vincent J., Van Essen DC, Raichle ME (2005). The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 102: 9673-9678
19. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K (2009). Optical deconstruction of parkinsonian neural circuitry. Science 324: 354-359
20. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci Transl Med 4: 128-152
21. Holtzheimer PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, Barrocas A et al. (2012). Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry 69: 150-158
22. Hyman SE (2007). Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci 8: 725-732
23. Hyman SE (2010). The diagnosis of mental disorders: The problem of reification. Annu Rev Clin Psychol 6: 155-179
24. Hyman SE (2012). Revolution stalled. Sci Transl Med 4: 155cm11
25. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al. (2010). Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry 167: 748-751
26. Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET et al. (2013). Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev pii: S0149-7634(13)00082-1; e-pub ahead of print
27. Institute of Medicine (2013). Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. The National Academies Press: Washington, DC, USA
28. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
29. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-99
30. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796
31. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633-647
32. Kessler RC, Chiu WT, Demler O, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 62: 617-627
33. Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP (2011). Exploratory analyses of efficacy data from major depressive disorder trails submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatr 72: S464-s472
34. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D et al. (2012). De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 17: 142-153
35. Konopka B, Friedrich T, Davis-Turak J, Winden K, Oldham MC, Gao F et al. (2012). Human specific transcriptional networks in the brain. Neuron 75: 601-617
36. Laborit H, Huguenard P, Alluaume R (1952). Un noveau stabilisateur vé gé tatif (le 4560 RP). Presse Med 60: 206-208
37. Lee SH, DeCandia TR, Ripke S, Yang J. the Schizophrenia Psychiatric Genome-Wide Association Study Consortium (PGC-SCZ); International Schizophrenia Consortium (ISC) et al. (2012). Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet 44: 247-250
38. Lewis DA, Sweet RA (2009). Schizophrenia from a neural circuitry perspective: Advancing toward rational pharmacological therapies. J Clin Invest 119: 706-716
39. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
40. Major Depressive Disorder Working group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM et al. (2013). A mega-Analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 18: 497-511
41. Myers RD, Veale WL (1968). Alcohol preference in the rat: Reduction following depletion of brain serotonin. Science 160: 1469-1471
42. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A et al. (2012). Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485: 242-245
43. Nestler EJ, Hyman SE (2010). Animal models of neuropsychiatric disorders. Nat Neurosci 13: 1161-1169
44. Peça J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN et al. (2011). Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472: 437-442
45. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC et al. International Schizophrenia Consortium (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 748-752
46. Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y et al. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physical interact and suggest underlying biology. PLoS Genet 7: E1001273
47. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Ritz L et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Eng J Med 354: 1231-1242
48. Sachs GS, Neirenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356: 1711-1722
49. Sahoo T, Theisen A, Rosenfeld JA, Lamb AN, Ravnan JB, Schultz RA et al. (2011). Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problems. Genet Med 13: 868-880
50. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ et al. (2012). De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485: 237-241
51. Schildkraut JJ, Kety SS (1967). Biogenic amines and emotion. Science 156: 21-37
52. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507-3512
53. Shendure J, Ji H. (2008). Next-generation DNA sequencing. Nat Biotechnol 26: 1135-1145
54. Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF, Woolf CJ et al. (2011). Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9: 205-218
55. Subramaniam K, Luks TL, Fisher M, Simpson GV, Nagarajan S, Vinogradov S (2012). Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron 73: 842-853
56. Sullivan PF, Daly MJ, O'Donovan M (2012). Genetic architecture of psychiatric disorders: The emerging picture and its implications. Nat Rev Genet 13: 537-551
57. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872
58. Takahashi K, Yamanaka S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676
59. Trivedi MH, Rush AJ, Wisniewski SR, Niernberg AA, Warden D et al. (2006). Evaluation of outcomes with citalopram for depression using measurementbased care in STAR. *D: Implications for clinical practice. Am J Psychiatry 163: 28-40
60. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V et al. (2010). Can animal models of disease reliably inform human studies? PLoS Med 7: E1000245
61. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. (2011). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2163-2196
62. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F et al. (2013). Onestep generation of mice carrying mutations in multiple genes by CRISPR/Casmediated genome engineering. Cell 153: 910-918
63. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR et al. (2012). Genome-wide association study of major depressive disorder: New results, meta-Analysis, and lessons learned. Mol Psychiatry 17: 36-48
64. Xu B, Hsu PK, Stark KL, Karayiorgou M, Gogos JA. (2013). Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. Cell 152: 262-275
65. Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ et al. (2013). A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12: 713-726
66. Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S et al. (2013). Rapid singlestep induction of functional neurons from human pluripotent stem cells. Neuron 78: 785-798